# Neuregen Therapeutics

Source: https://onco.cc/companies/neuregen-therapeutics/  
OnCo record `neuregen-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Neuregen Therapeutics is testing an injection for high-grade brain tumours that combines a cancer-killing virus, an immune booster and a technique meant to turn leftover tumour cells into cells that no longer divide.

## Summary

Neuregen Therapeutics Co., Ltd. (纽伦捷生物), whose Wuhan entity was founded in December 2021 according to the company and whose website gives a Shanghai address, develops therapies based on in vivo cell reprogramming (in situ transdifferentiation), with a pipeline focused on nervous system tumours and blinding eye disease. NRG-103 injection combines a recombinant oncolytic virus, an immune-enhancing cytokine and in situ transdifferentiation of residual tumour cells; the company reports FDA IND clearance and orphan drug designation, and implied IND approval from China's CDE in January 2026. A phase 1 trial is enrolling patients with recurrent or progressive high-grade glioma (NCT07710690). The company announced a Series A in May 2026, led by a Wuhan Optics Valley fund. Its first registered cancer trial, NCT07710690, was posted on ClinicalTrials.gov in July 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Neuregen Therapeutics Co., Ltd.; 纽伦捷生物医药科技（武汉）有限公司
- HQ: Wuhan
- Type: biotech
- Website: https://www.nrg-therapeutics.com/

## Notes

- Company profile, milestones and news (Chinese) read on 29 October 2026. The FDA designations are the company's own statements and were not checked against FDA records.

## Sources

- Official website: https://www.nrg-therapeutics.com/
- Company profile and milestones: https://www.nrg-therapeutics.com/company_profile.html
- ClinicalTrials.gov: phase 1 trial of NRG-103 in high-grade glioma (NCT07710690): https://clinicaltrials.gov/study/NCT07710690

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/), [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)

---
JSON: https://onco.cc/api/v1/entities/neuregen-therapeutics.json